Cortland Advisers Has Lowered Duke Energy (DUK) Holding By $568,799; 3 Analysts Covering Ergomed plc (LON:ERGO)

February 15, 2018 - By Darrin Black

Cortland Advisers Llc decreased Duke Energy Corp (DUK) stake by 3.24% reported in 2017Q3 SEC filing. Cortland Advisers Llc sold 6,853 shares as Duke Energy Corp (DUK)’s stock rose 6.39%. The Cortland Advisers Llc holds 204,921 shares with $17.20 million value, down from 211,774 last quarter. Duke Energy Corp now has $53.03 billion valuation. The stock increased 1.57% or $1.17 during the last trading session, reaching $75.76. About 2.78M shares traded. Duke Energy Corporation (NYSE:DUK) has risen 8.31% since February 15, 2017 and is uptrending. It has underperformed by 8.39% the S&P500.




Among 3 analysts covering Ergomed (LON:ERGO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ergomed had 32 analyst reports since September 29, 2015 according to SRatingsIntel. Numis Securities maintained it with “Buy” rating and GBX 275 target in Tuesday, May 2 report. The stock of Ergomed plc (LON:ERGO) has “Buy” rating given on Wednesday, October 21 by N+1 Singer. The rating was maintained by N+1 Singer with “Buy” on Tuesday, November 1. The company was maintained on Friday, October 6 by Numis Securities. The stock of Ergomed plc (LON:ERGO) earned “Buy” rating by N+1 Singer on Friday, April 21. On Tuesday, September 19 the stock rating was maintained by Numis Securities with “Buy”. The company was maintained on Tuesday, November 1 by Stifel Nicolaus. Numis Securities maintained Ergomed plc (LON:ERGO) rating on Monday, October 17. Numis Securities has “Buy” rating and GBX 267 target. The firm earned “Buy” rating on Thursday, January 25 by Numis Securities. The rating was maintained by Numis Securities on Tuesday, January 17 with “Buy”. See Ergomed plc (LON:ERGO) latest ratings:

01/02/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
25/01/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
15/12/2017 Broker: N+1 Singer Rating: Corporate Maintain
23/10/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 280.00 New Target: GBX 300.00 Maintain
06/10/2017 Broker: Numis Securities Rating: Buy New Target: GBX 280.00 Maintain
19/09/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain

The stock increased 1.50% or GBX 3 during the last trading session, reaching GBX 203. About 14,874 shares traded. Ergomed plc (LON:ERGO) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Ergomed plc provides clinical research, and drug development and safety services in the United Kingdom and rest of Europe, the Middle East, Africa, North America, Asia, and Australia. The company has market cap of 90.76 million GBP. The firm offers clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It has a 290 P/E ratio. It focuses on various therapeutic areas, including oncology, neurology, and immunology, as well as the development of orphan drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: